Immuneering Co. (NASDAQ:IMRX) Receives Consensus “Buy Moderate” Recommendation From Brokers

Shares of Immuneering Co. (NASDAQ:IMRX – Get Rating) have been assigned a consensus rating of “moderate buy” by the seven brokerages that currently cover the company, Marketbeat reports. One research analyst rated the stock with a hold rating and five gave the company a buy rating. The 12-month average target price among brokers who have reported on the stock in the past year is $31.33.

Several brokerages have published reports on IMRX. Chardan Capital began covering Immuneering shares in a research note on Friday. They set a “buy” rating and a target price of $18.00 on the stock. Oppenheimer began covering Immuneering in a report on Thursday, March 31. They set an “outperform” rating and a price target of $25.00 on the stock.

IMRX shares opened at $5.65 on Friday. Immuneering has a 52 week minimum of $3.74 and a 52 week maximum of $33.99. The company’s fifty-day moving average is $4.85 and its two-hundred-day moving average is $8.10. The stock has a market capitalization of $149.10 million and a PE ratio of -1.89.

Immuneering (NASDAQ:IMRX – Get Rating) last announced its results on Tuesday, May 10. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Immuneering had a negative return on equity of 38.00% and a negative net margin of 2,651.85%. The company posted revenue of $0.18 million for the quarter, versus analyst estimates of $0.22 million. On average, sell-side analysts expect Immuneering to post -2.15 EPS for the current year.

(A d)

If you’re new to trading, you’ve probably heard the wrong word about options, that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering strategy, you will soon learn that the safest option for new accounts is the options themselves!

In related news, Director Laurie Keating acquired 7,000 shares of Immuneering in a transaction that took place on Monday, May 16. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $35,000.00. Following the acquisition, the director now owns 14,000 shares of the company, valued at $70,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this link. Over the past 90 days, insiders have purchased 11,551 shares of the company worth $54,300.

A number of institutional investors and hedge funds have recently changed their holdings of IMRX. Millennium Management LLC purchased a new stake in Immuneering in Q3 valued at approximately $2,384,000. Metropolitan Life Insurance Co NY purchased a new stake in Immuneering during the third quarter worth approximately $75,000. Allspring Global Investments Holdings LLC acquired a new stake in Immuneering during the fourth quarter valued at approximately $149,000. The New York State Common Retirement Fund increased its stake in Immuneering by 172.8% during the fourth quarter. The New York State Common Retirement Fund now owns 4,637 shares of the company worth $75,000 after purchasing 2,937 additional shares during the period. Finally, Northern Trust Corp increased its stake in Immuneering by 4.5% during the fourth quarter. Northern Trust Corp now owns 75,891 shares of the company worth $1,227,000 after purchasing an additional 3,279 shares during the period. Hedge funds and other institutional investors hold 47.41% of the company’s shares.

About Immunization (Get an assessment)

Immuneering Corporation, a biopharmaceutical company, is focused on product candidates in oncology and neuroscience. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat cancer patients, including pancreatic cancer, melanoma, colorectal cancer and non-small cell lung cancer caused by mutations RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Featured articles

Analyst Recommendations for Immunization (NASDAQ:IMRX)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Immuneering right now?

Before you consider immunization, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Immuneering wasn’t on the list.

Although Immuneering currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Previous Sri Lanka's top five state-owned enterprises lose Rs 931 billion amid currency instability
Next Federal Government Announces Monkeypox Vaccine Allocation for Washington State